Actively Recruiting
Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide (COmPACt Study)
Led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Updated on 2025-04-09
10
Participants Needed
1
Research Sites
354 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Despite anti-thymocyte globulin has a mainstay role in preventing GvHD (and non-relapse mortality) in CB transplantation, it also induces delayed immune recovery, increased risk of cytomegalovirus and Epstein-Barr virus reactivation, post-transplant lymphoproliferative diseases, overall accounting for increased transplant-related mortality and/or increased relapse incidence. All these findings support the use of alternative approaches for in vivo T cell depletion in the setting of CB transplantation.
CONDITIONS
Official Title
Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide (COmPACt Study)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years old
- Receiving a cord blood unit transplant with total nucleated cells greater than 2.0 x10^7/kg and at least 4/6 HLA loci matched
- Undergoing a myeloablative conditioning regimen with either Thiotepa/Busulfan/Fludarabine or total body irradiation with Fludarabine
- Receiving graft-versus-host disease prophylaxis including post-transplant cyclophosphamide (30 mg/kg or more on days +3 and +5), cyclosporine, and mycophenolate mofetil
- Diagnosed with one of these hematological malignancies: Acute Myeloid Leukemia, Myelodysplastic Syndrome, high risk Acute Lymphoblastic Leukemia, Bi phenotypic or undifferentiated leukemia, Chronic Myeloid Leukemia resistant to TK inhibitors, Ph-negative Myeloproliferative Neoplasms, or resistant/relapsing Non-Hodgkin's lymphoma ineligible for autologous transplant
You will not qualify if you...
- Positive serologic markers for human immunodeficiency virus (HIV)
- Acute hepatitis B virus (HBV) infection
- Acute hepatitis C virus (HCV) infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, RM, Italy, 00168
Actively Recruiting
Research Team
A
Andrea Bacigalupo, Prof.
CONTACT
P
Patrizia Chiusolo, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here